Cytokinetics, Inc.
667 articles about Cytokinetics, Inc.
-
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
4/10/2024
Cytokinetics, Incorporated today announced three Late Breaking Clinical Trial presentations relating to SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), at Heart Failure 2024, an International Congress of the European Society of Cardiology, taking place in Lisbon, Portugal from May 11, 2024 – May 14, 2024.
-
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session
4/5/2024
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced additional 48-week data from FOREST-HCM the open label extension clinical study of aficamten in patients with hypertrophic cardiomyopathy (HCM), at the 73rd Annual American College of Cardiology (ACC) Scientific Session taking place from April 6, 2024 –April 8, 2024.
-
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session
4/5/2024
Cytokinetics, Incorporated announced additional 48-week data from FOREST-HCM, the open label extension clinical study of aficamten in patients with hypertrophic cardiomyopathy, at the 73rd Annual American College of Cardiology Scientific Session taking place from April 6, 2024 –April 8, 2024 in Atlanta, GA.
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 02, 2024
4/2/2024
Cytokinetics, Incorporated announced that on March 29, 2024 it granted stock options to purchase an aggregate of 78,000 shares of common stock to five new employees, whose employment commenced in March 2024, as a material inducement to their employment.
-
Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
4/1/2024
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024 at 2:15 PM Eastern Time.
-
Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session
3/25/2024
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four presentations at the American College of Cardiology 73rd Annual Scientific Session (ACC.24) taking place in Atlanta, GA from April 6, 2024 – April 8, 2024.
-
Cytokinetics to Participate in March 2024 Investor Conferences
3/4/2024
Cytokinetics, Incorporated announced that the company is scheduled to participate in the following investor conferences in March.
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 01, 2024
3/1/2024
Cytokinetics, Incorporated announced that on February 29, 2024 it granted stock options to purchase an aggregate of 28,500 shares of common stock to three new employees, whose employment commenced in February 2024, as a material inducement to their employment.
-
Cytokinetics, The Mended Hearts, Inc. and WomenHeart Announce Launch of New Initiative to Increase Engagement in Cardiovascular Clinical Trials
2/28/2024
Cytokinetics, Incorporated, together with The Mended Hearts, Inc. and WomenHeart: The National Coalition for Women with Heart Disease, announced the launch of ENACT: Empower, Navigate, Activate for Clinical Trials.
-
Cytokinetics Reports Fourth Quarter 2023 Financial Results
2/27/2024
Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the fourth quarter and full year 2023. Net loss for the fourth quarter was $136.9 million or $1.38 per share and the net loss for the year 2023 was $526.2 million or $5.45 per share.
-
Cytokinetics to Announce Fourth Quarter Results on February 27, 2024
2/13/2024
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 27, 2024 at 4:00 PM Eastern Time.
-
Cytokinetics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
2/6/2024
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024 at 10:40 AM Eastern Time.
-
Cytokinetics Announces Recipients of Its Sixth Annual Communications Grant Program
1/29/2024
Cytokinetics, Incorporated announced the recipients of its sixth annual Communications Grant Program, intended to support increased capacity in communications, awareness building and community engagement.
-
Cytokinetics Presents New Data at CMR 2024 From FOREST-HCM, the Open Label Extension Clinical Trial of Aficamten
1/25/2024
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data at CMR 2024 demonstrating favorable effects on cardiac structure, function and fibrosis related to treatment with aficamten in FOREST-HCM.
-
Cytokinetics Announces New Data From FOREST-HCM to be Presented at CMR 2024
1/18/2024
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced an upcoming presentation at CMR 2024 taking place online and in person in London, UK from January 25-27, 2024.
-
Dropping the potential Cytokinetics buy runs contrary to Novartis’ recent dealmaking frenzy, which included the acquisition of Calypso and three research collaborations.
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 03, 2024
1/3/2024
Cytokinetics, Incorporated announced that on December 29, 2023 it granted stock options to purchase an aggregate of 6,150 shares of common stock to three new employees, whose employment commenced in December 2023, as a material inducement to their employment.
-
Cytokinetics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/2/2024
Cytokinetics, Incorporated announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 7:30 AM Pacific Time in the Borgia Room of the Westin St. Francis Hotel in San Francisco, CA.
-
Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
12/27/2023
Cytokinetics, Incorporated announced positive topline results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.
-
Cytokinetics to Host Investor Call on December 27 to Discuss the Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy
12/26/2023
Cytokinetics, Incorporated announced that members of its senior management will host an investor call at 8:30 AM Eastern Time on Wednesday, December 27, 2023 to discuss the topline results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten, an investigational medicine, in patients with symptomatic obstructive hypertrophic cardiomyopathy.